{"cluster": 45, "subcluster": 6, "abstract_summ": "We report 3 cases of thrombocytopenia with anti\u2010platelet factor 4 antibodies among 16 intubated COVID\u201019 patients with adult respiratory distress syndrome, a higher than expected incidence of 19%.This case highlights the risk of delayed thromboembolic complications in patients with COVID-19 infection and the need to identify the subgroup of patients with a higher risk of thromboembolism, such as discharges to nursing homes and those in need of oxygen requirement; and those with underlying comorbid conditions that may require anticoagulation for a longer duration.Physicians should be aware of the increased VTE risk, strongly consider VTE screening, and use thromboprophylaxis in all hospitalized patients.Early reports of COVID\u201019 clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for COVID\u201019 patients with low molecular weight heparin, but this would be contraindicated in the presence of heparin\u2010induced thrombocytopenia (HIT).Since the writing of this guidance and the letter from the experts being sent to us, there have been several reports of very high incidence of both arterial and venous thromboembolism (TE) in patients with COVID-19.1,2,3 In one report published in the Journal of Thrombosis and Haemostasis, the incidence of venous TE was 25%, some of whom died from this complication.2 Laboratory markers including D-dimer were relevant in these patients.", "title_summ": "Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).A Case of COVID-19 Infection With Delayed Thromboembolic Complication on WarfarinLaboratory haemostasis monitoring in COVID\u201019Heparin\u2010induced Thrombocytopenia with Thrombosis in COVID\u201019 Adult Respiratory Distress SyndromeHeterogeneity in reporting venous thromboembolic phenotypes in COVID-19: Methodological issues and clinical implications.", "title_abstract_phrases": "We report 3 cases of thrombocytopenia with anti\u2010platelet factor 4 antibodies among 16 intubated COVID\u201019 patients with adult respiratory distress syndrome, a higher than expected incidence of 19%.Therefore, we summarize current evidence from the available literature and, on behalf of the German Society of Angiology (DGA), we aim to provide advice to establish an improved and more uniform strategy for thromboprophylaxis in patients with COVID-19.A Case of COVID-19 Infection With Delayed Thromboembolic Complication on WarfarinNovel coronavirus disease 2019 (COVID-19) pandemic has posed an unprecedented threat to humanity with more than eight million infections and 450,000 deaths reported worldwide so far.The role of heparin is being increasingly investigated in patients with COVID-19 infection; however, the role of other anticoagulants such as warfarin is yet to be defined.This case highlights the risk of delayed thromboembolic complications in patients with COVID-19 infection and the need to identify the subgroup of patients with a higher risk of thromboembolism, such as discharges to nursing homes and those in need of oxygen requirement; and those with underlying comorbid conditions that may require anticoagulation for a longer duration.Heparin\u2010induced Thrombocytopenia with Thrombosis in COVID\u201019 Adult Respiratory Distress SyndromeEarly reports of COVID\u201019 clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for COVID\u201019 patients with low molecular weight heparin, but this would be contraindicated in the presence of heparin\u2010induced thrombocytopenia (HIT)."}